Table 2.
Factors | p-value | Adjusted odds ratio (95% CI) |
---|---|---|
Age (<80 vs. ≥80 years) | 0.205 | 2.21 (0.65 – 8.11) |
Gender | p > 0.25 | |
Fracture level (TL vs. non-TL) | 0.001* | 11.67 (2.48 – 83.17) |
BMD at lumbar spine (≤ − 2.5 vs. > − 2.5 SD) | 0.001* | 11.68 (2.48 – 83.17) |
Pre-existing VCF | p > 0.25 | |
Posterior wall fracture | 0.001* | 8.53 (2.25 – 42.23) |
Past bisphosphonate use | 0.019* | 4.86 (1.29 – 22.09) |
Pharmaceutical agents (TPD vs. BP) | 0.002* | 8.15 (2.02 – 43.33) |
*p < 0.05, 95% CI 95% confidence interval, BMD bone mineral density, SD standard deviation, VCF vertebral compression fracture, TL thoracolumbar spine (T11-L2), non-TL non-thoracolumbar spine (T5-T10 or L3-L5), TPD teriparatide, BP bisphosphonatecme